Literature DB >> 18463385

A new weapon for attacking tumor blood vessels.

Gregg L Semenza1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18463385     DOI: 10.1056/NEJMcibr0800272

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  At the crossroads in the management of gastroesophageal junction carcinomas-where do we go from here?

Authors:  Rotonya McCants Carr; John P Lynch
Journal:  Gastrointest Cancer Res       Date:  2008-09

2.  Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye.

Authors:  Ulrich Schraermeyer; Sylvie Julien
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-05-22       Impact factor: 3.117

3.  Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

Authors:  Marc C Chamberlain; Sandra K Johnston
Journal:  J Neurooncol       Date:  2009-07-11       Impact factor: 4.130

Review 4.  Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Authors:  Michael S Magee; Adam E Snook; Glen P Marszalowicz; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

5.  Oral administration of blueberry inhibits angiogenic tumor growth and enhances survival of mice with endothelial cell neoplasm.

Authors:  Gayle Gordillo; Huiqing Fang; Savita Khanna; Justin Harper; Gary Phillips; Chandan K Sen
Journal:  Antioxid Redox Signal       Date:  2009-01       Impact factor: 8.401

6.  Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment.

Authors:  Alex Z Fu; Kristi D Graves; Roxanne E Jensen; John L Marshall; Margaret Formoso; Arnold L Potosky
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-18       Impact factor: 4.553

Review 7.  Review of Natural Product-Derived Compounds as Potent Antiglioblastoma Drugs.

Authors:  Moon Nyeo Park; Hyo Sook Song; Myungsun Kim; Min-Jung Lee; Whisung Cho; Hyun-Jin Lee; Cho-Hyun Hwang; Soojong Kim; Yechae Hwang; Beomku Kang; Bonglee Kim
Journal:  Biomed Res Int       Date:  2017-10-18       Impact factor: 3.411

8.  Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme.

Authors:  Wonyoung Kang; Sung Heon Kim; Hee Jin Cho; Juyoun Jin; Jeongwu Lee; Kyeung Min Joo; Do-Hyun Nam
Journal:  Oncotarget       Date:  2015-09-29

9.  Identification and characterization of angiogenesis targets through proteomic profiling of endothelial cells in human cancer tissues.

Authors:  Mehdi Mesri; Charlie Birse; Jenny Heidbrink; Kathy McKinnon; Erin Brand; Candy Lee Bermingham; Brian Feild; William Fitzhugh; Tao He; Steve Ruben; Paul A Moore
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

10.  BMAL1 Suppresses Proliferation, Migration, and Invasion of U87MG Cells by Downregulating Cyclin B1, Phospho-AKT, and Metalloproteinase-9.

Authors:  Do Hyeong Gwon; Woo-Yong Lee; Nara Shin; Song I Kim; Kuhee Jeong; Won-Hyung Lee; Dong Woon Kim; Jinpyo Hong; Sun Yeul Lee
Journal:  Int J Mol Sci       Date:  2020-03-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.